Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients

Laboratory Investigation

Volumn 86, Issue 8, 2006, Pages 781-789

  Gottumukkala, Raju V S R K ^a   Gavalas, Nikos G ^a   Akhtar, Samia ^a   Metcalfe, Russell A ^a   Gawkrodger, David J ^b   Haycock, John W ^a   Watson, Philip F ^a   Weetman, Anthony P ^a   Kemp, Elizabeth Helen ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Autoantibody; Autoantigen; Autoimmunity; Melanin concentrating hormone receptor; Melanocyte; Vitiligo

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; B LYMPHOCYTE ANTIGEN; HORMONE RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR; MELANIN CONCENTRATING HORMONE RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ARTICLE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; SYSTEMIC LUPUS ERYTHEMATOSUS; VITILIGO;

ADULT; AGED; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHO CELLS; CRICETINAE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, PITUITARY HORMONE; VITILIGO;

EID: 33746257411     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700438     Document Type: Article

References (37)

1. Howitz J, Brodthagen H, Schwartz M, et al. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:47-52.
2. Ortonne JP, Mosher DB, Fitzpatrick TB. Vitiligo and other hypomelanoses of hair and skin. In: Ortonne JP, Mosher DB, Fitzpatrick TB (eds). Topics in Dermatology. Plenum Medical Book Company: New York, USA, 1983, pp 257-258.
3. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993;129:994-998.
4. Le Poole IC, Das PK, van den Wijngaard RMJGJ, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993;2:145-153.
5. Pawelek J, Korner A, Bergstrom A. New regulation of melanin biosynthesis and autodestruction of melanoma cells. Nature 1980;286:617-619.
6. Nordlund JJ, Lerner AB. Vitiligo. It is important? Arch Dermatol 1982;118:5-8.
7. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-1085.
8. Ochi Y, DeGroot LJ. Vitiligo in Graves' disease. Ann Intern Med 1969;71:935-940.
9. Naughton GK, Eisinger M, Bystryn J-C. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983;158:246-251.
10. Ogg GS, Dunbar PR, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208.
11. Naughton GK, Reggiardo MD, Bystryn J-C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-981.
12. Harning R, Cui J, Bystryn J-C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991;97:1078-1080.
13. Norris DA, Kissinger RM, Naughton GK, et al. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocyes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988;90:783-789.
14. Gilhar A, Zelickson B, Ulman Y, et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995;105:683-686.
15. Song YH, Connor E, Li Y, et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994;344:1049-1052.
16. Baharav E, Merimski O, Shoenfeld Y, et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996;105:84-88.
17. 35S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997;109:69-73.
18. Kemp EH, Waterman EA, Gawkrodger DJ, et al. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998;139:798-805.
19. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998;111:1034-1039.
20. Kemp EH, Gawkrodger DJ, Watson PF, et al. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998;114:333-338.
21. Hedstrand H, Ekwall O, Olsson MJ, et al. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem 2001;276:35390-35395.
22. Lang KS, Caroli CC, Muhm A, et al. HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 2001;116:891-897.
23. Palermo B, Campanelli R, Garbelli S, et al. Specific cytotoxic T lymphocyte responses against MelanA/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001;117:326-332.
24. Kemp EH, Waterman EA, Hawes BE, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002;109:923-930.
25. Hawes BE, Kil E, Green B, et al. The melanin-concentrating hormone receptor couples to multiple G proteins to activate diverse intracellular signaling pathways. Endocrinology 2000;141:4524-4532.
26. Hoogduijn MJ, Ancans J, Suzuki I, et al. Melanin-concentrating hormone and its receptor are expressed and functional in human skin. Biochem Biophys Res Commun 2002;296:698-701.
27. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994;15:788-830.
28. Hoedemaekers AC, van Breda Vriesman PJ, De Baets MH. Myasthenia gravis as a prototype autoimmune receptor disease. Immunol Res 1997;16:341-354.
29. MacNeil S, Munroe DS, Metcalfe R, et al. An investigation of the ability of TSH and Graves' immunoglobulin G to increase intracellular calcium in human thyroid cells, rat FRTL-5 thyroid cells and eukaryotic cells transfected with the human TSH receptor. J Endocrinol 1994;143:527-540.
30. Metcalfe RA, Findlay C, Robertson WR, et al. Differential effect of thyroid-stimulating hormone (TSH) on intracellular free calcium and cAMP in cells transfected with the human TSH receptor. J Endocrinol 1998;157:415-424.
31. Metcalfe RA, Oh YS, Stroud C, et al. Analysis of antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease. Autoimmunity 1997;25:65-72.
32. Arikawa K, Ichikawa Y, Yoshida T, et al. Blocking type antithyrotropin receptor antibody in patients with nongoitrous hypothyroidism: its incidence and characteristics of action. J Clin Endocrinol Metab 1985;60:953-959.
33. Hara H, Hayashi K, Ohta K, et al. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis. Clin Chem 1993;39:2053-2057.
34. Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves' disease. Trends Endocrinol Metab 2005;16:243-248.
35. Kifor O, McElduff A, Leboff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004;89:548-556.
36. Morgenthaler NG, Tremble J, Huang G, et al. Binding of antithyrotropin receptor autoantibodies in Graves' disease serum to nascent, in vitro translated thyrotropin receptor: ability to map epitopes recognised by antibodies. J Clin Endocrinol Metab 1996;81:700-706.
37. Ajjan RA, Kemp EH, Waterman EA, et al. Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 2000;85:2020-2027.